48 results about "Antibiotics therapy" patented technology

The invention belongs to the technical field of microbial antibacterial preparations, and particularly discloses a novel strong vibrio parahaemolyticus bacteriophage isolated strain vBVpSCC6 and application of the novel strong vibrio parahaemolyticus bacteriophage isolated strain vBVpSCC6. The bacteriophage vBVpSCC6 is preserved in the Guangdong Microbial Culture Collection Center on September 14, 2020, and the preservation number is GDMCC (China General Microbiological Culture Collection Center) NO: 61189-B1. The bacteriophage has good tolerance to environments such as temperature, pH, ultraviolet rays and the like, and has a good prevention and control effect on aquatic product pollution caused by vibrio parahaemolyticus. The bacteriophage has a lysis effect on multi-drug-resistant vibrio parahaemolyticus, can replace antibiotics to play a bacteriostatic role, effectively solves the problem of drug resistance faced by current antibiotic treatment, and has relatively good utilization value and application prospect. The bacteriophage can also be prepared into a composition with other bacteriophages to play a synergistic effect, and the bacteriophage can be applied to wider-spectrum antibacterial or bacteriostatic application.

The present disclosure relates generally to methods of treating infections in overweight or obese patients using antibiotics.

Compounds and methods for combinatorial drug discovery in nanoliter droplets are described herein. More particularly, novel synergistic agents that increase efficacy of antibiotic agents to treat bacterial infections are described.

The invention belongs to the field of food nutrition and pharmacy, and particularly relates to folium mori crude polysaccharide and application thereof. An extract rich in mulberry leaf polysaccharide is extracted from mulberry leaves through a specific extraction process, and it is found through an in-vitro antibacterial experiment that the crude mulberry leaf polysaccharide has the direct inhibiting and killing effect on helicobacter pylori (Helicobacter pylori). In-vitro intestinal flora fermentation research shows that the folium mori crude polysaccharide can effectively correct intestinal flora disorder caused by triple antibiotics for treating helicobacter pylori, meanwhile, the short-chain fatty acid level is remarkably improved, and the helicobacter pylori abundance in intestinal flora is reduced. The application field of mulberry leaf polysaccharide is widened, and important reference is provided for developing products for adjuvant therapy of H.pylori infection and intestinal microecology regulation based on natural polysaccharide.

This invention provides the application of gonococcal ferritin in the preparation of anti-gonococcal products, relating to the field of antibody technology. The application of gonococcal ferritin subunits in the preparation of antibodies against gonococcal ferritin inhibits gonococcal infection by intervening in the iron metabolism pathway of gonococci, without inducing classic drug resistance mutations. This overcomes the limitations of existing technologies that rely on antibiotics, achieving broad-spectrum inhibition of drug resistance lineages. It solves the technical problem in existing technologies where multidrug / pan-drug resistance of gonococci leads to complete failure of antibiotic treatment, and the lack of therapeutic targets targeting its core survival mechanisms.

The invention discloses a culture method based on posthypoxia gastric intima separation treatment of freshwater white pomfret, and relates to the technical field of aquaculture and disease prevention and control. The method comprises the following steps: step 1, identifying hypoxia symptoms; 2, medicine compatibility feeding is carried out; 3, regulating and controlling the water body environment; 4, breeding environment management; and step 5, continuous monitoring. According to the invention, the food maternal, the endothelium corneum gigeriae galli and the pipemidic acid are combined for the separation treatment of the endogastric membranes of the aquatic animals for the first time, the thinking limitation of traditional disease prevention and treatment is broken through, the traditional Chinese and western medicine theories are organically combined, and a new disease prevention and treatment thought is provided for the aquaculture industry; compared with a traditional pure antibiotic treatment or water quality improvement method, the scheme is high in pertinence and directly aims at a core pathological link of gastric intima separation after hypoxia; the comprehensive treatment effect is good, and meanwhile, anti-infection, mucous membrane repair and function regulation are considered; and the used medicines are all common medicines, have small side effects and low residues, and meet the safety requirements of aquatic products.

Disclosed herein are compounds, compositions, and methods for treating infections by bacteria and for killing bacteria. In particular, the disclosed compounds, compositions, and methods are useful for treating infections by bacteria and for killing persister bacteria that survive antibiotic treatment and then reconstitute infections.

The present invention relates to compositions and methods for preventing and / or treating bacterial disease (e.g., disease caused by Neisseria spp. such as Neisseria gonorrhoeae or Neisseria meningitidis). In particular, the present invention provides compositions comprising an effective amount of a nucleic acid, wherein such compositions are capable of killing or inhibiting the growth of a Neisseria spp and sensitizing Neisseria spp to antibiotic treatment.

The invention discloses a gelled cell as well as a preparation method and application thereof. Relates to the field of synthetic biology and biomedicine. The gelated cell is a cell structure without cell viability, and comprises: a carrier cell framework comprising a cell membrane which retains the membrane protein content, the type and the lipid order of an original carrier cell; the intracellular hydrogel is formed in situ in the carrier cell framework through supramolecular host-guest interaction or cross-linking reaction, and is fused with the inner surface of a cell membrane; the antibacterial substance is loaded in the intracellular hydrogel; wherein pores are distributed on the cell membrane, the intracellular hydrogel is communicated with the external environment through the pores, and the loaded antibacterial substances are exposed. The gelated cell provided by the invention can simultaneously realize targeted delivery, contact sterilization and endotoxin adsorption, and avoids the problem of secondary inflammation caused by release of endotoxin in traditional antibiotic therapy and the problem of membrane protein loss or disordered arrangement in a cell membrane coating technology.

The invention discloses a feed additive for replacing antibiotics to treat chicken necrotic enteritis and application of the feed additive, and belongs to the technical field of feed. The effective component of the feed additive is the tannin extract from chestnut trees, and animal experiments prove that the tannin extract from chestnut trees can improve the production performance of broiler chickens with necrotic enteritis to a certain extent, improve the intestinal morphology and immune function of the broiler chickens with necrotic enteritis and improve the immunity of the broiler chickens with necrotic enteritis. Therefore, the chestnut tree tannin extract can replace antibiotics and has a good treatment effect on broiler intestinal inflammation caused by clostridium perfringens and coccidiosis.

The invention discloses a bacteriostasis-related protein as well as a biological material and application thereof. The technical problem to be solved by the invention is how to inhibit bacteria. The invention specifically discloses application of the G enzyme. The application is any one of the following items: A1) application in preparation of a product for promoting wound healing; a2) in preparation of a product for promoting healing of infectious wounds; a3) in preparation of a product for promoting and / or assisting in promoting wound healing; a4) in preparation of a product for enhancing the antibacterial and / or bactericidal ability of antibiotics; a5) application in preparation of a product for enhancing the ability of antibiotics to treat or / and prevent eye infection; a6) in improving the cell activity and / or preparing a product for improving the cell activity. The G enzyme is any one of the following items: B1) the amino acid sequence is a protein of a sequence 1 or 31-442 sites of the sequence 1; b2) a protein which is obtained by substitution and / or deletion and / or addition of amino acid residues of the protein B1), has 80% or more of identity with the protein B1) and has the same activity with the protein B1); b3), a fusion protein obtained by connecting the N terminal or / and the C terminal of B1) or B2) with a protein tag. The G enzyme disclosed by the invention has an obvious antibacterial effect when being used for gram-negative bacteria, and can be used for industrial production.

The invention relates to the technical field of biological medicines, in particular to mRNA (messenger Ribonucleic Acid) for coding a single-chain antibody resisting staphylococcus aureus and application of the mRNA. On the basis of a specific scFv with high affinity to staphylococcus aureus lysate, cell wall protein and toxin, the mRNA is optimized by a gene sequence and is matched with a functional element suitable for in-vivo expression of the mRNA, so that stable and efficient expression of the mRNA in a target tissue is ensured. The mRNA is further prepared into an mRNA-LNP preparation, and the preparation is beneficial to delivery of the mRNA to local tissues of the mammary gland of the dairy cow, expresses scFv protein with a specific antibacterial function in epithelial cells of the mammary gland, can be used for replacing traditional antibiotics to treat the mastitis of the dairy cow caused by staphylococcus aureus, and has an outstanding treatment effect.

Compositions of hyaluronic acid (HA) conjugated with antibiotics are disclosed for a rapid release antibiotic delivery system into a closed space to achieve rapid therapeutic range within 24 hours and effective elimination of the antibiotic within 80-120 hours. In particular, this invention is directed to compositions, method of preparation, and method of treatment to prevent invention using porous and non-porous embodiments of hyaluronic acid polymer conjugated with antibiotics or other therapeutic agents for rapid therapeutic delivery and controlled reduction of therapeutic dosages of antibiotics to prevent invention and reduce antibiotic resistance. Low concentration of crosslinkers conjugated with HA as well as using porogens and functional group modifiers allow other therapeutic to be conjugated to HA such as sugars and steroids. Suspension of HA conjugates in chitosan enable additional treatment means. Anti-cancer therapeutic agents may also be conjugated for controlled release using this system.

Methods for identifying and providing information about inhibiting growth of polymicrobial infections, including but not limited to providing statistics or information about the likelihood of success in inhibiting growth of a polymicrobial infection with particular compositions or therapeutic solutions. The methods herein feature detection and identification of organisms of the polymicrobial sample (e.g., polymicrobial infection), phenotypic pooled sensitivity tests for determining the susceptibility or resistance of the polymicrobial sample (e.g., polymicrobial infection) in the sample to an antibiotic or other therapeutic agent, and identification of resistance genes, e.g., genetic markers that may indicate resistance to a particular treatment. Together, the data can be applied against databases of antibiotic / therapeutic susceptibility or resistance for particular known polymicrobial samples (e.g.. polymicrobial infections) in order to provide information related to the likelihood of success of one or more therapeutic solutions for the polymicrobial sample (e.g.. polymicrobial infection).

The present invention provides a method of identifying an animal for which antibiotic treatment, anti-infective treatment, probiotic treatment, immunostimulant treatment, additional monitoring and / or a separate or alternative management strategy is appropriate, comprising: a) collecting a sample from said animal; b) performing a leukocyte differential cell count on said sample; c) comparing said leukocyte differential cell count of (b) with an index of infection; and d) initiating antibiotic treatment, anti-infective treatment, probiotic treatment, immunostimulant treatment, additional monitoring and / or a separate or alternative management strategy of said animal on the basis of said comparing step.

The present application belongs to the technical field of microbial prevention and treatment, and particularly relates to a mycobacterium phage and application thereof. Specifically, the present application successfully screens a mycobacterium phage MP1 capable of precisely targeting and killing mycobacterium marinum, which can precisely target and kill specific mycobacterium marinum without causing adverse effects on normal flora. This feature enables the phage therapy to avoid the adverse reactions and flora imbalance problems caused by antibiotic treatment when treating drug-resistant mycobacterium marinum. Meanwhile, the above-mentioned mycobacterium phage MP1 is obtained from nature and is easy to be industrialized, and a drug or environmental disinfectant prepared from the above-mentioned phage not only can reduce the cost, but also has the advantages of green environmental protection and the like, and therefore has good practical application value.

Provided herein are postbiotic compositions prepared using successive fermentation methods of specific bacteria and plant fiber material. Also provided herein are methods, including for the treatment or prevention of the disruption of gut microbiota, or dysbiosis, associated with an antibiotic treatment, chemotherapy treatment, or administration of a dysbiosis-causing medications or medical treatments, using said postbiotic compositions, or for improving responses and / or reducing complications to treatments such as antibiotics or chemotherapy. Such postbiotic compositions can also be used for the treatment or prevention of the disruption of the gut-brain axis, including to treat or prevent neurological diseases or disorders, such as synucleinopathies, including but not limited to Parkinson's disease.

The invention relates to a microwave-responsive antibacterial repair-promoting bismuth telluride-based thermoelectric material as well as preparation and application thereof, and belongs to the technical field of biological medicines. The microwave-responsive antibacterial and repair-promoting bismuth telluride-based thermoelectric material comprises zinc oxide-bismuth telluride. The preparation method of the microwave-responsive antibacterial and repair-promoting bismuth telluride-based thermoelectric material comprises the following steps: dissolving bismuth nitrate pentahydrate and polyvinylpyrrolidone in ethylene glycol to obtain a solution A; dissolving sodium hydroxide and sodium tellurite in ethylene glycol to obtain a solution B; dissolving zinc oxide in ethylene glycol to obtain a solution C; mixing the solution A, the solution B and the solution C, heating the mixed solution, and reacting to obtain a reaction product; and carrying out post-treatment on the reaction product to prepare the zinc oxide-bismuth telluride. When the microwave-responsive antibacterial and repair-promoting bismuth telluride-based thermoelectric material provided by the invention is used for wound infection treatment, related risks of antibiotic treatment can be avoided, mycoderm can be effectively removed, and wound repair can be continuously promoted.

A formulation for treating middle ear infections is a blend of mustard oil and lavender essential oil, for application in treating middle ear infections. A proportion in the formulation of lavender oil to the mustard oil, by volume is from, 5% to 45%.

Bacterial species and the associated microbiome persist in tumors and metastases. Antibiotic treatment selectively reduces microbiome-induced tumor growth and can advantageously be included in treatment regimens. Accordingly, the present disclosure relates to, for example, the diagnosing cancer in a subject and providing identifying an effective treatment regimen for the subject.

This invention provides the use of peony leaf or its extract in the preparation of a medicament for treating vaginitis. This invention also provides the use of peony leaf extract in combination with carboxymethyl chitosan in the preparation of an antibacterial drug, wherein the peony leaf extract is a methanol extract of peony leaves. This invention further provides a hydrogel loaded with peony leaf extract, prepared from carboxymethyl chitosan (CMCS) and peony leaf extract as raw materials, wherein the peony leaf extract is a methanol extract of peony leaves, and the mass ratio of peony leaf extract to carboxymethyl chitosan (CMCS) is (5-20):(100-150); wherein it contains 25-35 mg / mL of total flavonoids and 195-205 mg / mL of total polyphenols. This invention combines peony leaf extract (PLE) and carboxymethyl chitosan (CMCS) to endow the hydrogel with excellent antibacterial and antioxidant capabilities, effectively treating vaginitis caused by various bacterial infections. It avoids the drug resistance that arises from antibiotic treatment, providing a new drug delivery strategy for the safe and effective treatment of vaginitis.

The present invention relates to probiotic bacteria of the species E. coli, in particular in combination with bacteria of the species Klebsiella oxytoca, that are used for a decolonization of pathogenic and / or multidrug resistant (MDR) Enterobacteria, such as pathogenic E. coli and / or Klebsiella pneumoniae (K. pneumoniae), Enterococci and / or Acinetobacter, from the gut of a subject. The decolonization can both be therapeutic, i.e. after colonization of the gut by the pathogenic and / or multi-resistant pathogen(s), or as a preventive measure before a re-colonization of the gut, as required after antibiotic treatment or treatment-induced dysbiosis.

The application discloses application of gentiopicroside in preparation of a medicine for preventing and controlling viral or bacterial infection. At present, the main prevention strategy for infectious diseases is to develop vaccines, and corresponding antibiotic treatment can be considered for bacterial infection treatment, but at present, antibiotics also have the problem of multiple drug resistance, and specific drugs for viral infection are still lacking. The application starts from the angle of improving the body's own anti-infection immunity, finds effective components for preventing and controlling infection from natural compounds, and provides a new candidate medicine for preventing and controlling infection.

This invention discloses a method for preparing TCPP / Emodin composite photocatalysts and their antibacterial applications, belonging to the field of pharmaceutical antibacterial medicine. Addressing the issues of drug resistance easily induced by traditional antibiotics in treating bacterial infections, performance defects in existing photocatalysts, and insufficient antibacterial capacity of single antibacterial materials, this invention leverages the advantages of tetracarboxyphenylporphyrin (TCPP)—strong visible light capture ability and low photogenerated electron-hole recombination rate—and complements emodin's π-conjugated system and its structural advantage of promoting carrier migration. The two are covalently linked through a chemical coupling mechanism involving EDC / NHS synergistic activation of the carboxyl group. Through steps such as dissolution, mixing reaction, dialysis purification, and freeze-drying, spherical TCPP / Emodin composite nanomaterials with a particle size of 100-500 nm are obtained. This composite material reduces the photogenerated electron-hole recombination rate and improves carrier migration efficiency, efficiently generating ROS under visible light irradiation, and exhibits excellent photodynamic antibacterial properties.

The present application relates to the technical field of biological medicine, and provides a bacteriophage for lysing high-toxicity multi-drug resistant Klebsiella pneumoniae and application thereof.The bacteriophage is Klebsiella pneumoniae phage vB_KpnP_XY3, and the preservation number is CCTCC NO: M 2025022.The bacteriophage can lyse high-toxicity multi-drug resistant Klebsiella pneumoniae 32416 carrying blaTEM, blaSHV, phoQ, pmrB drug resistance genes and rmpA, kfuBC, ybtA, iro-NB, fim-H, ureA, uge, wabG virulence genes, and has great potential in clinical application, and is an ideal choice for replacing antibiotics to treat multi-drug resistant bacteria.The bacteriophage vB_KpnP_XY3 not only widens host spectrum and lysis capacity, but also has broad application potential in clinical treatment of multi-drug resistant Klebsiella pneumoniae infection and environmental purification.

The invention discloses dihydromyricetin copper for treating swine pasteurellosis and a preparation method of the dihydromyricetin copper. According to the method, a synthetic reaction of a complex is carried out in an ethanol-ammonium acetate buffer solution with the pH value of 3.7; the optimal feeding molar ratio of the copper salt solution to the dihydromyricetin is 1.1: 2.0; the optimal reflux reaction time is 30 minutes. The complex is stable in activity and good in antibacterial effect on pig pasteurella multocida. The invention also provides a preparation method of the complex, and the method is simple, easy to control, suitable for large-scale production, high in product yield and high in purity, and is expected to become a medicine for replacing antibiotics to treat swine pasteurellosis.

The present application relates to a kind of microwave response antibacterial promotes the repair of bismuth telluride-based thermoelectric material and preparation and application, belong to biological medicine technical field.The microwave response antibacterial promotes the repair of bismuth telluride-based thermoelectric material includes zinc oxide-bismuth telluride.The preparation method of the microwave response antibacterial promotes the repair of bismuth telluride-based thermoelectric material, including the following steps: bismuth nitrate pentahydrate and polyvinylpyrrolidone are dissolved in ethylene glycol to obtain solution A;Sodium hydroxide and sodium tellurite are dissolved in ethylene glycol to obtain solution B;Zinc oxide is dissolved in ethylene glycol to obtain solution C;Solution A, solution B and solution C are mixed, and the mixed solution is heated, and reaction product is prepared by reaction;The reaction product is treated, and zinc oxide-bismuth telluride is prepared.The microwave response antibacterial promotes the repair of bismuth telluride-based thermoelectric material provided by the present application can not only avoid the related risk of antibiotic treatment when being used for wound infection treatment, but also effectively remove bacterial film and continuously promote wound repair.

The invention discloses a cell-penetrating peptide CPP151 as well as a compound, a composition and application thereof, and belongs to the technical field of polypeptides. According to the application, the cell-penetrating peptide CPP151 which is only internalized by THP1 (M0) cells is screened out from a plague bacillus sORF library through laser confocal and flow cytometry (FACS). The cell-penetrating peptide CPP151 can be used as a THP1 specific delivery carrier, and can be coupled with drugs (such as antibiotics and siRNA) to treat intracellular infection or immune diseases. The cell-penetrating peptide CPP151 can also be used as a diagnostic marker for detecting related pathological states of immune cells.

This invention belongs to the food or pharmaceutical field, specifically relating to a probiotic and prebiotic composition, its preparation process, and its application. The composition includes probiotics, resistant dextrin, xylooligosaccharides, fructooligosaccharides, stachyose, erythritol, and cranberry powder, prepared using a fluidized bed spray granulation process. As an adjuvant to antibiotics, this composition has been verified in animal and clinical trials to synergistically treat upper / lower respiratory tract infections and urinary tract infections, shorten symptom duration, accelerate recovery from the primary disease, maintain intestinal flora diversity, increase the abundance of beneficial bacteria such as Bifidobacteria, reduce the incidence of adverse reactions, and alleviate antibiotic-associated diarrhea. This invention provides a microecological restoration solution for antibiotic treatment, possessing clear clinical value and technological feasibility.